Crescent Biopharma, Inc. (CBIO) Free Cash Flow by Year
Crescent Biopharma, Inc. recorded an outflow of $72.5M in free cash flow in fiscal year 2025. This represents a decrease of 132.9% from the prior fiscal year. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to an outflow of $73.6M in free cash flow. The table below carries 14 fiscal years, from 2012 to 2025, and the quarters Crescent Biopharma, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
CBIO Free Cash Flow by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | TTM | FY2510-K | FY24DEF 14A | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1510-K | FY1410-K | FY1310-K | FY1210-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -$73.6M | -$72.5M-132.9% | -$31.1M+10.9% | -$34.9M+25.0% | -$46.5M+19.1% | -$57.5M-46.3% | -$39.3M+24.6% | -$52.1M-20.0% | -$43.5M-44.6% | -$30.1M+1.2% | -$30.4M-257.6% | -$8.5M-89.4% | -$4.5M+71.2% | -$15.6M-44.8% | -$10.8M |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
CBIO Free Cash Flow by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
What free cash flow means
Free cash flow is the cash operations produced over the period, less what the company spent on property, plant and equipment, so it answers what was left over rather than what was earned on paper.
More Crescent Biopharma, Inc. financials
Frequently Asked Questions
What was Crescent Biopharma, Inc.'s free cash flow in fiscal year 2025?
Crescent Biopharma, Inc. recorded an outflow of $72.5M in free cash flow in fiscal year 2025.
How fast is Crescent Biopharma, Inc.'s free cash flow growing?
Crescent Biopharma, Inc. (CBIO) free cash flow fell by 132.9% year over year, from -$31.1M to -$72.5M in fiscal year 2025.
What is Crescent Biopharma, Inc.'s free cash flow over the last twelve months?
Crescent Biopharma, Inc. (CBIO) reported an outflow of $73.6M in free cash flow over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
How has Crescent Biopharma, Inc.'s free cash flow changed over the years?
Across the 14 fiscal years this page covers, Crescent Biopharma, Inc. (CBIO) free cash flow went from -$10.8M in fiscal year 2012 to -$72.5M in fiscal year 2025.
What was Crescent Biopharma, Inc.'s free cash flow in the most recent quarter?
Crescent Biopharma, Inc. (CBIO) reported -$19.5M in free cash flow in Q2 2026. This represents a decrease of 17.7% from the same quarter a year earlier.
What does free cash flow mean on a financial statement?
Free cash flow is the cash operations produced over the period, less what the company spent on property, plant and equipment, so it answers what was left over rather than what was earned on paper. This page lists what Crescent Biopharma, Inc. (CBIO) reported on that line in every period on record.